Long-term treatment response and patient outcomes for vestibular schwannoma patients treated with hypofractionated stereotactic radiotherapy

Mira A. Patel, Ariel E. Marciscano, Chen Hu, Ignacio Jusué-Torres, Rupen Garg, Arif Rashid, Howard W. Francis, Michael Lim, Kristin J. Redmond, Daniele Rigamonti, Lawrence R. Kleinberg

Research output: Contribution to journalArticlepeer-review


Purpose: The aim of this study is to evaluate long-term treatment outcome and toxicities among vestibular schwannoma (VS) patients treated with hypofractionated stereotactic radiotherapy (HSRT). Methods: 383 patients with unilateral VS treated with HSRT (25 Gy, five fractions) between 1995 and 2007 were retrospectively reviewed. Treatment failure was defined as requiring salvage microsurgery. Posttreatment new/progressive clinical symptoms or increases in baseline tumor volume (BTV) due to treatment effect or progression were noted. Symptom outcomes were reported as baseline and posttreatment ± improvement, respectively. Symptoms were grouped by cranial nerve (CN) VII or CNVIII. Audiometry was assessed baseline and posttreatment hearing. Patients were grouped as having greater than serviceable hearing [Gardner Robertson (GR) score 1-2] or less than non-serviceable hearing (GR score 3-5) by audiometry. results: Median follow-up was 72.0 months. Nine (2.3%) experienced treatment failure. At last follow-up, 74 (19.3%) had new/progressive symptoms and were categorized as radiologic non-responders, whereas 300 (78.3%) had no tumor progression and were grouped as radiologic responders. Average pretreatment BTV for treatment failures, radiologic non-responders, and radiologic responders was 2.11, 0.44, and 1.87 cm3, respectively. Pretreatment CNVII and CNVIII symptoms were present in 9.4 and 93.4% of patients, respectively. Eight (24%) with pre-HSRT CNVII and 37 (10%) with pre-HSRT CNVIII symptoms recovered CN function post-HSRT. Thirty-five (9%) and 36 (9.4%) experienced new CNVII and CNVIII deficit, respectively, after HSRT. Of these, 20 (57%) and 18 (50%) recovered CNVII and CNVIII function, respectively, after HSRT. Evaluable audiograms were available in 199 patients. At baseline and at last follow-up, 65.8 and 36.2% had serviceable hearing, respectively. Fifty-one percent had preservation of serviceable hearing at last follow-up. conclusion: Treatment of VS with HSRT is effective with treatment success in 97.7% and an acceptable toxicity profile. Less than one-third of patients experience any new CNVII or CNVIII deficit posttreatment. Greater than 50% of patients with serviceable hearing at baseline maintained hearing function. Improved methods to differentiate treatment effect and tumor progression are needed.

Original languageEnglish (US)
Article number200
JournalFrontiers in Oncology
Issue numberSEP
StatePublished - Sep 4 2017


  • Acoustic neuroma
  • Cranial nerves
  • Hearing loss
  • Hypofractionated radiotherapy
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Long-term treatment response and patient outcomes for vestibular schwannoma patients treated with hypofractionated stereotactic radiotherapy'. Together they form a unique fingerprint.

Cite this